Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TDO2 | P48775 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153358 | 0.94 | ADRB2 (0.62) | ADRB2ESR1PDCD1ESR2CD274 | |
| Ammonia Solution, Strong SCHEMBL7978172 | 0.92 | ADRB2 (0.59) | ADRB2ESR1PDCD1ESR2CD274 | |
| SCHEMBL15423680 | 0.84 | ADRB2 (0.52) | ADRB2ESR1PDCD1ESR2CD274 | |
| SCHEMBL18682149 | 0.84 | IDO1 (0.54) | ADRB2ESR1PDCD1ESR2CD274 | |
| SCHEMBL15338275 | 0.84 | IDO1 (0.54) | ADRB2ESR1PDCD1ESR2CD274 | |
| SCHEMBL686394 | 0.84 | IDO1 (0.54) | ADRB2ESR1PDCD1ESR2CD274 | |
| SCHEMBL12229870 | 0.82 | IDO1 (0.62) | ADRB2ESR1PDCD1ESR2CD274 | |
| Ammonia Solution, Strong SCHEMBL11329287 | 0.82 | IDO1 (0.52) | ADRB2ESR1PDCD1ESR2CD274 | |
| SCHEMBL6935122 | 0.82 | ADRB2 (0.50) | ADRB2ESR1PDCD1ESR2CD274 | |
| SCHEMBL8972212 | 0.82 | ESR1 (0.76) | ADRB2ESR1PDCD1ESR2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924391-B2 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-6492550-B2 | INHIBITORS OF THE CYTOSOLIC PHOSPHOLYPASE A2 ENZYMES | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020068722-A1 | Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-06 | — | — | US | disclosed |
| US-20020037875-A1 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-28 | — | — | US | disclosed |
| US-6350892-B1 | ENZYME INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037875-A1 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | PLA2G4B, PLA2G4A, PLA2G1B | ADRB2 416/4885ESR1 2866/4885PDCD1 4734/4885 |
| US-20020068722-A1 | Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors | PLA2G4B, PLA2G4A, PLA2G1B | ADRB2 1138/4885ESR1 3497/4885PDCD1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.